New clinical trials presented at the American Diabetes Association's Scientific Sessions show that survodutide has promising results for reducing HbA1c levels and improving insulin sensitivity, with additional favorable changes in glucose-related biomarkers.
EULAR has released new guidelines for managing cardiovascular risk in rheumatic and musculoskeletal diseases, focusing on regular screening, managing traditional and disease-related risk factors, and patient education.